FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:931-932 August 27, 2009 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

To the Editor: Bose et al. (May 14 issue)¹ report on a patient with hereditary hemorrhagic telangiectasia (HHT) who was treated with bevacizumab for epistaxis. Our patient was a 55-year-old man with HHT (endoglin mutation P.LYS402.FS) with intractable pain and frequent episodes of pancreatitis related to pancreatic arteriovenous malformations. Surgery and embolization were not feasible. An indium-111–labeled bevacizumab single-photon-emission computed tomographic (CT) scan² showed elevated tracer uptake in the arteriovenous malformations. Bevacizumab at a dose of 5.0 mg per kilogram of body weight every 2 weeks was started 1 year ago. This treatment immediately stopped the epistaxis, the skin vascular . . . [Full Text of this Article]

Related Letters:

Bevacizumab in Hereditary Hemorrhagic Telangiectasia
Bose P., Holter J. L., Selby G. B.
Extract | Full Text | PDF  
N Engl J Med 2009; 360:2143-2144, May 14, 2009. Correspondence

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2010 Massachusetts Medical Society. All rights reserved.